Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Acetyl Sulfafurazole→

Acetyl Sulfafurazole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
80-74-0
Molecular formula
C13H15N3O4S
Molecular weight
309.34 g/mol
Drug class
Sulfonamide antibacterialsulfafurazole (sulfisoxazole) derivative
Mechanism of action
Competitively inhibits dihydropteroate synthase, preventing incorporation of para-aminobenzoic acid into dihydrofolic acid and thereby suppressing bacterial folate synthesis.
Indications / reported uses
  • Historical use for infections caused by susceptible bacteria, including selected urinary-tract and ear infections. Current availability and antimicrobial role are limited; use should follow current susceptibility data and local guidance.

Sources: NLM MeSH — Sulfisoxazole/acetylsulfafurazole · PubMed — Sulfisoxazole antimicrobial pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Acetyl Sulfafurazole Environmental Risk Assessment (ERA) (the Acetyl Sulfafurazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.